These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10561327)

  • 41. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability.
    Lai A; Filka E; McGibbon B; Nghiemphu PL; Graham C; Yong WH; Mischel P; Liau LM; Bergsneider M; Pope W; Selch M; Cloughesy T
    Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1372-80. PubMed ID: 18355978
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypofractionated intensity-modulated radiotherapy for primary glioblastoma multiforme.
    Floyd NS; Woo SY; Teh BS; Prado C; Mai WY; Trask T; Gildenberg PL; Holoye P; Augspurger ME; Carpenter LS; Lu HH; Chiu JK; Grant WH; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):721-6. PubMed ID: 14967426
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide.
    Chinot OL; Barrié M; Fuentes S; Eudes N; Lancelot S; Metellus P; Muracciole X; Braguer D; Ouafik L; Martin PM; Dufour H; Figarella-Branger D
    J Clin Oncol; 2007 Apr; 25(12):1470-5. PubMed ID: 17442989
    [TBL] [Abstract][Full Text] [Related]  

  • 44. RSR13, a potential athletic performance enhancement agent: detection in urine by gas chromatography/mass spectrometry.
    Breidbach A; Catlin DH
    Rapid Commun Mass Spectrom; 2001; 15(24):2379-82. PubMed ID: 11746905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hyperfractionated and accelerated-hyperfractionated radiotherapy for glioblastoma multiforme.
    Nieder C; Nestle U; Ketter R; Kolles H; Gentner SJ; Steudel WI; Schnabel K
    Radiat Oncol Investig; 1999; 7(1):36-41. PubMed ID: 10030622
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme.
    Singh D; Banerji AK; Dwarakanath BS; Tripathi RP; Gupta JP; Mathew TL; Ravindranath T; Jain V
    Strahlenther Onkol; 2005 Aug; 181(8):507-14. PubMed ID: 16044218
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
    Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
    Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
    Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Open-label simultaneous radio-chemotherapy of glioblastoma multiforme with topotecan in adults.
    Gross MW; Altscher R; Brandtner M; Haeusser-Mischlich H; Chiricuta IC; Siegmann AD; Engenhart-Cabillic R
    Clin Neurol Neurosurg; 2005 Apr; 107(3):207-13. PubMed ID: 15823676
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacological correction of hypothermic P(50) shift does not alter outcome from focal cerebral ischemia in rats.
    Wainwright MS; Sheng H; Sato Y; Mackensen GB; Steffen RP; Pearlstein RD; Warner DS
    Am J Physiol Heart Circ Physiol; 2002 May; 282(5):H1863-70. PubMed ID: 11959653
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bevacizumab in combination with radiotherapy and temozolomide for patients with newly diagnosed glioblastoma multiforme.
    van Linde ME; Verhoeff JJ; Richel DJ; van Furth WR; Reijneveld JC; Verheul HM; Stalpers LJ
    Oncologist; 2015 Feb; 20(2):107-8. PubMed ID: 25582142
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase I study of topotecan plus cranial radiation for glioblastoma multiforme: results of Radiation Therapy Oncology Group Trial 9507.
    Fisher BJ; Scott C; Macdonald DR; Coughlin C; Curran WJ
    J Clin Oncol; 2001 Feb; 19(4):1111-7. PubMed ID: 11181676
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Addition of bevacizumab to standard radiation therapy and daily temozolomide is associated with minimal toxicity in newly diagnosed glioblastoma multiforme.
    Vredenburgh JJ; Desjardins A; Kirkpatrick JP; Reardon DA; Peters KB; Herndon JE; Marcello J; Bailey L; Threatt S; Sampson J; Friedman A; Friedman HS
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):58-66. PubMed ID: 21036490
    [TBL] [Abstract][Full Text] [Related]  

  • 55. RSR13, a synthetic allosteric modifier of hemoglobin, enhances recovery of stunned myocardium in dogs.
    Pagel PS; Hettrick DA; Montgomery MW; Kersten JR; Warltier DC
    Adv Exp Med Biol; 1998; 454():527-31. PubMed ID: 9889932
    [No Abstract]   [Full Text] [Related]  

  • 56. A phase I dose-escalation study (ISIDE-BT-1) of accelerated IMRT with temozolomide in patients with glioblastoma.
    Morganti AG; Balducci M; Salvati M; Esposito V; Romanelli P; Ferro M; Calista F; Digesù C; Macchia G; Ianiri M; Deodato F; Cilla S; Piermattei A; Valentini V; Cellini N; Cantore GP
    Int J Radiat Oncol Biol Phys; 2010 May; 77(1):92-7. PubMed ID: 19683876
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase I trial of erlotinib with radiation therapy in patients with glioblastoma multiforme: results of North Central Cancer Treatment Group protocol N0177.
    Krishnan S; Brown PD; Ballman KV; Fiveash JB; Uhm JH; Giannini C; Jaeckle KA; Geoffroy FJ; Nabors LB; Buckner JC;
    Int J Radiat Oncol Biol Phys; 2006 Jul; 65(4):1192-9. PubMed ID: 16626884
    [TBL] [Abstract][Full Text] [Related]  

  • 58. GliaSite brachytherapy boost as part of initial treatment of glioblastoma multiforme: a retrospective multi-institutional pilot study.
    Welsh J; Sanan A; Gabayan AJ; Green SB; Lustig R; Burri S; Kwong E; Stea B
    Int J Radiat Oncol Biol Phys; 2007 May; 68(1):159-65. PubMed ID: 17331666
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of an allosteric modifier of hemoglobin, RSR-4, on oxygen affinity and oxygen saturation of hemoglobin in rabbits.
    Uchida K; Reilly MP; Abraham DJ; Asakura T
    Jpn J Physiol; 1998 Dec; 48(6):439-44. PubMed ID: 10021497
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Allosteric modifiers of hemoglobin. 1. Design, synthesis, testing, and structure-allosteric activity relationship of novel hemoglobin oxygen affinity decreasing agents.
    Randad RS; Mahran MA; Mehanna AS; Abraham DJ
    J Med Chem; 1991 Feb; 34(2):752-7. PubMed ID: 1995897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.